Announced Thu, 2 Jul · 21:22 IST

FY26 PAT surges 170% to Rs 263 lakh; operating cash flow sharply negative

Pat Growth 25pctNegative Operating CashflowResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.0%1-day move

₹6.00

prior close

₹6.06

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

—+3.1——+0.0-4.5-6.3+5.0-3.2-7.2-16.0———

Up moveDown movePending

AI summary

Dipna Pharmachem posted FY26 total income of Rs 1,291 crore, up 3.3% from Rs 1,249 crore. FY26 PAT rose 170% to Rs 263 lakh from Rs 97 lakh. Steel segment drove profit at Rs 867 lakh while Chemicals swung to a Rs 512 lakh loss. Q4 was weak with income falling sharply to Rs 20.5 crore from Rs 159 crore. EPS rose to Rs 1.00. Operating cash flow was sharply negative at Rs 1,832 lakh vs Rs 919 lakh. Auditor Devadiya and Associates issued an unmodified opinion. No deviations in preferential warrant funds use.

Likely market impact

Steel segment turnaround offset Chemicals weakness, lifting full-year profit. Weak Q4 and negative cash flow are areas to watch.